Angiotensin II blockade has become a standard anti-fibrotic therapy in renal diseases
because it slows progression to end-stage renal disease. However, current data support the
notion that angiotensin II blockade alone cannot stop progressive fibrotic disease. Of an
increasing number of therapies showing efficacy in animal studies, antibodies to
transforming growth factor β are the most thoroughly studied and are likely to be effective in
human clinical trials. However, hints exist in the literature suggesting that no single agent …